T4692
Anti-Transforming Growth Factor-β3 antibody produced in goat
affinity isolated antibody, lyophilized powder
Synonym(s):
Anti-TGF-β3
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
UNSPSC Code:
51111800
MDL number:
biological source
goat
conjugate
unconjugated
antibody form
affinity isolated antibody
antibody product type
primary antibodies
clone
polyclonal
form
lyophilized powder
species reactivity
human
technique(s)
immunohistochemistry (formalin-fixed, paraffin-embedded sections): 5-15 μg/mL, indirect ELISA: suitable, neutralization: suitable, western blot: 0.1 μg/mL
UniProt accession no.
application(s)
research pathology
storage temp.
−20°C
Gene Information
human ... TGFB3(7043)
General description
Transforming growth factor-β3 (TGF-β3) belongs to the TGF-β superfamily of secreted proteins. TGF-β3 has been implicated in the physiology of adult lung, brain and heart. The TGF-β family is involved in a variety of signaling pathways that involve serine/threonine protein kinases. TGF-β3 acts through binding to TGF-βR2 transmembrane receptor in mammals. The important pathways regulated by TGF-β3 are the Alk-5/SMAD, RhoA/Rho-kinase and MAPK pathways. TGF-β3 is involved in morphogenesis, development of palate, angiogenesis, induction of epithelial-mesenchymal transition Deregulation of TGF-β signaling has been implicated in many developmental syndromes and cancer progression
Anti-Transforming Growth Factor-b3 (TGF-β3) recognizes human and chicken TGF-β3. The antibody shows less than 25 % cross-reactivity with amphibian TGF-b5 and less than 10 % cross-reactivity with TGF-β1, TGF-β1.2, and TGF-β2. This antibody also shows less than 5 % cross-reactivity with recombinant human LAP (latency associated peptide, TGF-β1).
Anti-Transforming Growth Factor-b3 (TGF-β3) recognizes human and chicken TGF-β3. The antibody shows less than 25 % cross-reactivity with amphibian TGF-b5 and less than 10 % cross-reactivity with TGF-β1, TGF-β1.2, and TGF-β2. This antibody also shows less than 5 % cross-reactivity with recombinant human LAP (latency associated peptide, TGF-β1).
Immunogen
Recombinant chicken transforming growth factor-β3 (TGF-β3) expressed in Sf 21 cells.
Application
Anti- Transforming growth factor-β3 (TGF-β3) antibody may be used for immunoblotting at a working concentration of 0.1 μg/ml. For immunohistochemistry a working concentration of 5-15 μg/ml may be used. The antibody is suitable for neutralization reactions (ND50 is 0.01-0.05 μg/ml).
Physical form
Lyophilized from a 0.2 μm filtered solution of PBS with 5% trehalose.
Not finding the right product?
Try our Product Selector Tool.
Storage Class
10 - Combustible liquids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
P John Hart et al.
Nature structural biology, 9(3), 203-208 (2002-02-19)
Transforming growth factor-beta (TGF-beta) is the prototype of a large family of structurally related cytokines that play key roles in maintaining cellular homeostasis by signaling through two classes of functionally distinct Ser/Thr kinase receptors, designated as type I and type
Carl-Henrik Heldin et al.
FEBS letters, 586(14), 1959-1970 (2012-06-20)
Transforming growth factor-β (TGFβ) suppresses tumor formation since it inhibits cell growth and promotes apoptosis. However, in advanced cancers TGFβ elicits tumor promoting effects through its ability to induce epithelial-mesenchymal transition (EMT) which enhances invasiveness and metastasis; in addition, TGFβ
Wing-Yee Lui et al.
Endocrinology, 144(4), 1139-1142 (2003-03-18)
Recent studies using Sertoli cells cultured in vitro to permit tight junction (TJ) assembly have shown that TJ dynamics are regulated, at least in part, by TGF-beta3 via the p38 mitogen activated protein (MAP) kinase pathway. This in turn regulates
Marek Dudas et al.
Developmental biology, 266(1), 96-108 (2004-01-20)
Cleft palate is among the most common birth defects in humans, caused by a failure in the complex multistep developmental process of palatogenesis. It has been recently shown that transforming growth factor beta3 (Tgf-beta3) is an absolute requirement for successful
Vesa Kaartinen et al.
International journal of molecular medicine, 9(6), 563-570 (2002-05-16)
TGFbeta-induced epithelio-mesenchymal transdifferentiation (EMT) has been shown to play a pivotal role in developmental processes such as palatogenesis and heart organogenesis. Interestingly, EMT has also been shown to contribute to the promotion of invasiveness during the later stages of tumorigenesis.
Related Content
Instructions
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service